Drug Safety and Availability
Information for consumers and health professionals on new drug warnings and other safety information, drug label changes, and shortages of medically necessary drug products.
Drug Safety Communications
- FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
- FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
- FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer
Drug Recalls
- MS Bionic, Inc. Issues a Voluntary Nationwide Recall of All Lots of Megajex Natural Male Sex Enhancer Dietary Supplement
- Raritan Pharmaceuticals Inc. Issues a Voluntary Nationwide Recall of Products Containing Belladonna Extract Due to the Possibility of the Presence of Belladonna Alkaloids
- Tri-Coast Pharmacy Inc. Voluntarily Recalling All Sterile Products Prepared Between May 17, 2016 and November 17, 2016 Due to Concern Over Lack of Sterility Assurance
Drug Safety Labeling Changes
Drug Shortages
Subscribe
Sign up to receive emails about Recalls